Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Trial, single-center, randomized, double-blind, to demonstrate a lower incidence of acute diaphragmatic paralysis of the brachial plexus block with interscalene approach in arthroscopic shoulder surgery after administration of 25 mg of 0.25% Levobupivacaine compared to 50 mg administration

Next Previous
Trial Profile

Phase III Clinical Trial, single-center, randomized, double-blind, to demonstrate a lower incidence of acute diaphragmatic paralysis of the brachial plexus block with interscalene approach in arthroscopic shoulder surgery after administration of 25 mg of 0.25% Levobupivacaine compared to 50 mg administration

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levobupivacaine (Primary)
  • Indications Anaesthesia
  • Focus Therapeutic Use
  • Acronyms REDOLEV; REDOLEV-2019

Most Recent Events

  • 09 Aug 2022 Status changed from recruiting to completed.
  • 19 Apr 2021 Trial design, published in the Trials
  • 15 Mar 2021 Planned End Date changed from 15 Jan 2021 to 15 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top